Hyperresistinemia is associated with postmenopausal breast cancer

Menopause

Volumn 20, Issue 8, 2013, Pages 845-851

  Dalamaga, Maria ^a,b   Karmaniolas, Konstantinos ^b   Papadavid, Evangelia ^a   Pelekanos, Nicolaos ^a   Sotiropoulos, George ^c   Lekka, Antigoni ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b KAT HOSPITAL   (Greece)

^c ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

Adiponectin; Breast cancer; Leptin; Postmenopausal; Resistin; Risk factors

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; INSULIN; INTERLEUKIN 6; LEPTIN; RESISTIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOLIC BEVERAGE; ANTHROPOMETRY; ARTICLE; BODY MASS; BREAST; BREAST CANCER; CANCER HORMONE THERAPY; DISEASE ASSOCIATION; EDUCATION; FAMILY HISTORY; FEMALE; HUMAN; HYPERRESISTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MENARCHE; OBESITY; PHYSICAL ACTIVITY; POSTMENOPAUSE; SMOKING;

EID: 84881376586     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31827f06dc     Document Type: Article

References (46)

1. Vogel VG. Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer. Menopause 2008;15: 782-789.
2. Zaman K, Bodmer A, Pralong F, Castiglione-Gertsch M. Breast cancer and obesity, a dangerous relation. Rev Med Suisse 2012;8: 1101-1104.
3. Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15: 241-249.
4. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 2012;156: 635-648.
5. Rinaldi S, Key TJ, Peeters PHM, et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer 2006;118: 2832-2839. (Pubitemid 43673364)
6. Trichopoulos D, Adami H-O, Ekbom A, Hsieh C-C, Lagiou P. Early life events and conditions and breast cancer risk: from epidemiology to etiology. Int J Cancer 2008;122: 481-485. (Pubitemid 350308937)
7. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2: 133-140. (Pubitemid 33585924)
8. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001;286: 2143-2151. (Pubitemid 34044116)
9. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obesity Rev 2004;5: 153-165. (Pubitemid 38998240)
10. Dalamaga M. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer Potential preventive and therapeutic perspectives and challenges. Med Hypotheses 2012;79: 617-621.
11. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist 2011;16: 726-729.
12. Pobst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6: 165-173. (Pubitemid 29260048)
13. Bo S, Benso A, Durazzo M, Ghigo E. Does use of metformin protect against cancer in Type 2 diabetes mellitus? J Endocrinol Invest 2012;35: 231-235.
14. Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010;152: 93-100.
15. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012;33: 547-594.
16. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89: 1102-1107. (Pubitemid 38368397)
17. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009;133: 157-170.
18. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009;44: 685-690.
19. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010; 101: 1286-1291.
20. Kumor A, Daniel P, Pietruczuk M, Maaecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 2009;24: 275-281.
21. Šlǧeanu A, Tucureanu C, Lerescu L, et al. Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life 2010; 3: 416-420.
22. Gonullu G, Kahraman H, Bedir A, Bektas A, Yucel I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis 2010;25: 205-212.
23. Danese E, Montagnana M, Minicozzi AM, et al. The role of resistin in colorectal cancer. Clin Chim Acta 2012;413: 760-764.
24. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007;22: 117-121.
25. Hou WK, Xu YX, Yu T. Adipocytokines and breast cancer risk. Chin Med J 2007;120: 1592-1596. (Pubitemid 47595751)
26. Gaudet MM, Falk RT, Gierach GL, et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol 2010;34: 580-586.
27. Hlavna M, Kohut L, Lipkova J, et al. Relationship of resistin levels with endometrial cancer risk. Neoplasma 2011;58: 124-128.
28. Housa D, Vernerova Z, Heracek J, et al. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression. Neoplasma 2008;55: 442-446.
29. Dalamaga M, Karmaniolas K, Panagiotou A, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control 2009; 20: 193-199.
30. Dalamaga M, Karmaniolas K, Nikolaidou A, et al. Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer 2008;44: 1744-1753.
31. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 2006; 28: 241-244. (Pubitemid 44735917)
32. Sun CA, Wu MH, Chu CH, et al. Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat 2010;123: 869-876.
33. Lee YC, Chen YJ, Wu CC, Lo S, Hou MF, Yuan SS. Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecol Oncol 2012;125: 742-750.
34. Dalamaga M, Karmaniolas K, Kontos F, Migdalis I, Dionyssiou-Asteriou A. Clinical study on the serum carcinoembryonic antigen, CA 19-9, CA 50, and >-fetoprotein levels in patients with myelodysplastic syndromes. Leuk Lymphoma 2006;47: 1782-1787. (Pubitemid 44649760)
35. Dalamaga M, Nikolaidou A, Karmaniolas K, et al. Circulating adiponectin and leptin in relation to myelodysplastic syndrome: a case-control study. Oncology 2007;73: 26-32. (Pubitemid 351465597)
36. Dalamaga M, Archondakis S, Sotiropoulos G, et al. Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas 2012;71: 301-308.
37. Dalamaga M, Karmaniolas K, Papadavid E, et al. Elevated serum visfatin/ nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause 2011;18: 1198-1204.
38. Kassi E, Dalamaga M, Hroussalas G, et al. Adipocyte factors, highsensitive C-reactive protein levels and lipoxidative stress products in overweight postmenopausal women with normal and impaired OGTT. Maturitas 2010;67: 72-77.
39. Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. Int J Oncol 2002;21: 1285-1292.
40. Maggio AB, Wacker J, Montecucco F, et al. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr 2012;161: 1022-1027.
41. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002;10: 1-5. (Pubitemid 135686624)
42. Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One 2006;1:e31.
43. Di Simone N, Di Nicuolo F, Sanguinetti M, et al. Resistin regulates human choriocarcinoma cell invasive behaviour and endothelial cell angiogenic processes. J Endocrinol 2006;189: 691-699.
44. Balducci S, Zanuso S, Nicolucci A, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis 2010;20: 608-617.
45. Phoenix KN, Vumbaca F, Fox MM, Evans R, Claffey KP. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat 2010;123: 333-344.
46. Bo S, Ciccone G, Durazzo M, et al. Efficacy of antioxidant treatment in reducing resistin serum levels: a randomized study. PLoS Clin Trials 2007;2:e:17.